Mesothelioma Cancer Resources Blog

Rationale The purpose of this study is to evaluate the antitumor activity of a combination of Imatinib mesylate and Gemcitabine in patients with unresectable malignant mesothelioma expressing either PDGFR-beta or C-kit. Date First Received: October 29, 2007 Last Updated: October 29, 2007 Verified by: Gruppo Italiano Mesotelioma, October 2007 Clinical Trial Phase: Phase 2 Start …

Date First Received: March 29, 2008 Last Updated: April 2, 2008 Verified by: Intergroupe Francophone de Cancerologie Thoracique, April 2008 Clinical Trial Phase: Phase 2/Phase 3 | Start Date: February 2008 Overall Status: Recruiting Estimated Enrollment: 445 Brief Summary Official Title: “A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, …

Date First Received: April 9, 2007 Last Updated: March 18, 2008 Verified by: National Cancer Institute (NCI), April 2007 Clinical Trial Phase: Phase 2 | Start Date: February 2007 Overall Status: Recruiting Estimated Enrollment: 76 Brief Summary Official Title: “Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma” RATIONALE: …

Date First Received: August 8, 2007 Last updated: March 18, 2008 Verified by: National Cancer Institute (NCI), August 2007 Clinical Trial Phase: Phase 2 | Start Date: May 2006 Overall Status: Recruiting Estimated Enrollment: 111 Brief Summary Official Title: “An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant …

The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives… Date First Received: March 5, 2008 Last Updated: March 5, 2008 Verified by: European Lung Cancer Working Party, March 2008 Clinical Trial Phase: Phase 2 | Start Date: …

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin… Date First Received: March 11, 2008 Last Updated: March 17, 2008 …

Date First Received: December 15, 2007 Last Updated: April 1, 2008 Verified by: National Cancer Institute (NCI), March 2008 Clinical Trial Phase: Phase 1 Start Date: June 2007 Overall Status: Recruiting Estimated Enrollment: 24 Condition Keyword(s): Malignant Mesothelioma Intervention(s): Drug: SS1(dsFv)-PE38 immunotoxin Drug: cisplatin Drug: pemetrexed disodium Procedure: chemotherapy Procedure: immunoenzyme technique Procedure: immunohistochemistry staining …

Primary Objective: 1. To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: 1. To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: 1. histologic analysis of biopsy tissue 2. by non-invasive assessments of tumor vascularity performed… Date …

The purpose of this research study is to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed… …

Date First Received: March 29, 2006 Last Updated: December 25, 2007 Verified by: National Cancer Institute (NCI), June 2007 Clinical Trial Phase: Phase 2 | Start Date: December 2005 Overall Status: Recruiting Estimated Enrollment: 50 Brief Summary Official Title: “Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma” RATIONALE: AZD2171 may stop the …